News | October 07, 2022
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
India has the second-largest number of adults with diabetes globally, after China
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Subscribe To Our Newsletter & Stay Updated
